clofibric acid has been researched along with Hypertension in 11 studies
Clofibric Acid: An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
clofibric acid : A monocarboxylic acid that is isobutyric acid substituted at position 2 by a p-chlorophenoxy group. It is a metabolite of the drug clofibrate.
Hypertension: Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Etofibrate is a hypolipemic drug belonging to the fibrate class." | 2.69 | Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome. ( Chelstowski, K; Jastrzebska, M; Kopciewicz, J; Naruszewicz, M; Pieczul-Mróz, J; Torbus-Lisiecka, B, 1999) |
| "Greater than 60% of patients with type 2 diabetes will have retinopathy." | 2.44 | Update on the treatment of diabetic retinopathy. ( Miller, AG; Wilkinson-Berka, JL, 2008) |
| "The role of dyslipidemia is essential in the development of atherosclerosis, therefore continuing care of dyslipidemic patients is an extremely important task in cardiovascular prevention." | 1.33 | [Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care]. ( Ilyés, I; Jancsó, Z; Simay, A; Varga, Z, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (9.09) | 18.2507 |
| 2000's | 10 (90.91) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mutez, E | 1 |
| Duhamel, A | 1 |
| Defebvre, L | 1 |
| Bordet, R | 1 |
| Destée, A | 1 |
| Kreisler, A | 1 |
| Zhao, X | 1 |
| Kandoussi, A | 1 |
| Martin, F | 1 |
| Hazzan, M | 1 |
| Noël, C | 1 |
| Fruchart, JC | 1 |
| Staels, B | 1 |
| Duriez, P | 1 |
| Ashen, MD | 1 |
| Blumenthal, RS | 1 |
| Halabi, CM | 1 |
| Sigmund, CD | 1 |
| Jancsó, Z | 1 |
| Varga, Z | 1 |
| Simay, A | 1 |
| Ilyés, I | 1 |
| Elijovich, F | 1 |
| Wu, J | 1 |
| Province, MA | 1 |
| Coon, H | 1 |
| Hunt, SC | 1 |
| Eckfeldt, JH | 1 |
| Arnett, DK | 1 |
| Heiss, G | 1 |
| Lewis, CE | 1 |
| Ellison, RC | 1 |
| Rao, DC | 1 |
| Rice, T | 1 |
| Kraja, AT | 1 |
| Wilkinson-Berka, JL | 1 |
| Miller, AG | 1 |
| Suliburska, J | 1 |
| Duda, G | 1 |
| Jastrzebska, M | 1 |
| Torbus-Lisiecka, B | 1 |
| Pieczul-Mróz, J | 1 |
| Chelstowski, K | 1 |
| Kopciewicz, J | 1 |
| Naruszewicz, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Treatment Study for Severe High-Density Lipoprotein Deficiency[NCT00458055] | 19 participants (Actual) | Interventional | 2006-11-30 | Completed | |||
| Effect of Tomato Consumption on Serum High Density Lipoprotein-cholesterol Levels. A Randomized, Open-label, Single Blind, Clinical Trial[NCT01342666] | 50 participants (Actual) | Interventional | 2009-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To evaluate the effect of two daily tomatoes consumption on HDL-c levels. (NCT01342666)
Timeframe: Baseline and after one month
| Intervention | mg/dL (Mean) | |
|---|---|---|
| Baseline HDL-c | Final HDL-c | |
| Cucumber Consumption | 36.8 | 35.8 |
| Tomato Consumption | 36.5 | 41.6 |
3 reviews available for clofibric acid and Hypertension
| Article | Year |
|---|---|
Clinical practice. Low HDL cholesterol levels.
Topics: Adult; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diet, Fat-Restricted; Drug T | 2005 |
Clinical practice. Low HDL cholesterol levels.
Topics: Adult; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diet, Fat-Restricted; Drug T | 2005 |
Clinical practice. Low HDL cholesterol levels.
Topics: Adult; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diet, Fat-Restricted; Drug T | 2005 |
Clinical practice. Low HDL cholesterol levels.
Topics: Adult; Alcohol Drinking; Cholesterol; Cholesterol, HDL; Clofibric Acid; Diet, Fat-Restricted; Drug T | 2005 |
Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
Topics: Alkanesulfonates; Animals; Atherosclerosis; Clinical Trials as Topic; Clofibric Acid; Humans; Hypert | 2005 |
Update on the treatment of diabetic retinopathy.
Topics: Adrenal Cortex Hormones; Aldehyde Reductase; Angiotensin II; Antihypertensive Agents; Blood Glucose; | 2008 |
1 trial available for clofibric acid and Hypertension
| Article | Year |
|---|---|
Etofibrate decreases factor VII and fibrinogen levels in patients with polymetabolic syndrome.
Topics: Arteriosclerosis; Clofibric Acid; Diabetes Mellitus, Type 1; Factor VII; Fibrinogen; Humans; Hyperli | 1999 |
7 other studies available for clofibric acid and Hypertension
| Article | Year |
|---|---|
Lipid-lowering drugs are associated with delayed onset and slower course of Parkinson's disease.
Topics: Clofibric Acid; Diabetes Complications; Dyslipidemias; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2009 |
Prevention of local lipotoxicity: a new renoprotective mechanism of peroxisome proliferator-activated receptor-alpha activation in hypertension and obesity?
Topics: Animals; Clofibric Acid; Dietary Fats; Humans; Hypertension; Hypolipidemic Agents; Kidney Diseases; | 2009 |
HMG-CoA reductase inhibition and PPAR- alpha activation both inhibit cyclosporin A induced endothelin-1 secretion in cultured endothelial cells.
Topics: Animals; Aorta; Cattle; Cells, Cultured; Clofibric Acid; Cyclosporine; Endothelin-1; Endothelium, Va | 2002 |
[Continuing care of patients with cardiovascular risk in general practice: patients with dyslipidemia and their care].
Topics: Adult; Aged; Body Mass Index; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Continuity | 2005 |
20-HETE and salt-sensitivity of blood pressure a novel emerging concept.
Topics: Animals; Clofibric Acid; Cytochrome P-450 CYP4A; Humans; Hydroxyeicosatetraenoic Acids; Hypertension | 2006 |
An investigation of the effects of lipid-lowering medications: genome-wide linkage analysis of lipids in the HyperGEN study.
Topics: Adult; Aged; Black or African American; Clofibric Acid; Female; Genetic Linkage; Genetic Markers; Ge | 2007 |
[Analysis of dietary habits and dietary intake in hypertensive smokers].
Topics: Adult; Antioxidants; Body Mass Index; Calcium; Cholesterol; Clofibric Acid; Diet; Diet Records; Fatt | 2007 |